A rare Wall Street downgrade questions the obesity pill story

Eli Lilly's stock dropped more than 7% after investment bank HSBC downgraded the drugmaker from "hold" to "reduce" on Tuesday, March 17 ^[1]. The stock fell 5.9% that day alone, making it the second-worst performer in the S&P 500 ^[2]. The downgrade was notable because Wall Street has been almost uniformly bullish on Lilly for three years ^[1].

HSBC analyst Rajesh Kumar said the market is "overexcited" about Lilly's upcoming obesity pill, orforglipron, sold under the brand Foundayo ^[1]. Assuming a launch this summer, Wall Street analysts expect the pill to bring in between $1.1 billion and $1.3 billion in sales this year ^[1]. Kumar warned that patients may take pills less consistently than injections, telling Bloomberg that "compliance and persistence on orals can be potentially lower than on injectables" ^[1]. He also said Lilly's stock is "priced to perfection," leaving little room for the company to disappoint ^[1].

A second concern involves competitor Novo Nordisk, which makes semaglutide drugs Ozempic and Wegovy. Novo has been cutting prices, which could pressure Lilly's own pricing for tirzepatide products Mounjaro and Zepbound ^[1]. Kumar also pointed to a longer-term risk: generic copies of semaglutide, which started launching in India this month, could eventually "collapse" pricing across the whole obesity-drug market ^[1]. Separately, MarketWatch reported that HSBC's analysts worry that middle-class Americans who pay cash for Zepbound could struggle to keep affording it if job losses tied to AI reduce household budgets ^[2].

The two firms' 2026 outlooks diverge sharply. Lilly's own guidance points to a 25% revenue increase at the midpoint of its range, while Novo is projecting a sales decline of 5% to 13% ^[1]. Kumar said Wall Street is currently betting on a "stairway to heaven" trajectory for Lilly and a "complete collapse" at Novo, even though the two companies compete in the same market and their fortunes are closely linked ^[1]. HSBC's own estimate for the total obesity-drug market by 2032 is $80 billion to $120 billion, well below the broader analyst consensus of $150 billion ^[1].

Among major drugmakers, Lilly was the only one to have its rating changed in HSBC's latest sector review. Biogen and Novartis kept "reduce" ratings, while Novo Nordisk kept a "hold" alongside Bristol Myers and Gilead. AbbVie, Amgen, Bayer, Johnson & Johnson, Merck, Pfizer, Roche and Sanofi all kept "buy" ratings ^[1].

Why it matters for patients

This downgrade is a debate among stock analysts, not a change to any drug's safety or approval status. But the underlying arguments touch on things patients care about directly. One is price: if Novo's price cuts and future generic semaglutide competition do squeeze the market the way HSBC predicts, that could eventually affect what patients pay for GLP-1 drugs, though the timeline for that is not stated in these sources ^[1]. Another is who can keep affording treatment. MarketWatch's reporting on HSBC's note raises the question of whether cash-paying patients — many of whom fall outside insurance coverage for weight-loss drugs — could scale back or stop treatment if their financial situations get tighter ^[2]. Neither source states what this would mean for any individual patient's coverage or out-of-pocket costs going forward.

What happens next

Orforglipron's launch is expected in early summer 2026, and how patients actually use the pill — including whether they stick with it as consistently as injectable versions — will be one of the first real tests of Kumar's compliance concerns ^[1]. Generic semaglutide launches in India this month are an early signal of the broader pricing risk HSBC flagged, though no timeline is given in these sources for when similar generic competition might reach the United States ^[1].